164 related articles for article (PubMed ID: 35562875)
1. Examination of the Impact of CYP3A4/5 on Drug-Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach.
He Q; Bu F; Wang Q; Li M; Lin J; Tang Z; Mak WY; Zhuang X; Zhu X; Lin HS; Xiang X
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562875
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the Impact of
He Q; Bu F; Zhang H; Wang Q; Tang Z; Yuan J; Lin HS; Xiang X
Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33673653
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling.
Zhang H; Bu F; Li L; Jiao Z; Ma G; Cai W; Zhuang X; Lin HS; Shin JG; Xiang X
Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):331-340. PubMed ID: 28945011
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
5. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.
Cheng F; Li Q; Wang J; Zeng F; Zhang Y
J Clin Pharm Ther; 2021 Dec; 46(6):1636-1649. PubMed ID: 34342024
[TBL] [Abstract][Full Text] [Related]
6. Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats.
Wei H; Tao X; Di P; Yang Y; Li J; Qian X; Feng J; Chen W
Drug Metab Dispos; 2013 Jul; 41(7):1398-403. PubMed ID: 23628674
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetic study of tacrolimus and
Qu J; Bian R; Liu B; Chen J; Zhai J; Teng F; Guo W; Wei H
Front Pharmacol; 2022; 13():956166. PubMed ID: 36188616
[No Abstract] [Full Text] [Related]
9. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
10. The Pharmacokinetic Prediction of Cyclosporin A after Coadministration with Wuzhi Capsule.
Fan J; Chen L; Lu X; Li M; Zhu L
AAPS PharmSciTech; 2019 Jul; 20(6):247. PubMed ID: 31286321
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients.
Teng F; Zhang W; Wang W; Chen J; Liu S; Li M; Li L; Guo W; Wei H
Biopharm Drug Dispos; 2022 Apr; 43(2):76-85. PubMed ID: 35220592
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.
Gong F; Hu H; Ouyang Y; Liao ZZ; Kong Y; Hu JF; He H; Zhou Y
Toxicol Appl Pharmacol; 2023 May; 466():116475. PubMed ID: 36931438
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine.
Zuo XC; Zhou YN; Zhang BK; Yang GP; Cheng ZN; Yuan H; Ouyang DS; Liu SK; Barrett JS; Li PJ; Liu Z; Tan HY; Guo R; Zhou LY; Xie YL; Li ZJ; Li J; Wang CJ; Wang JL
Drug Metab Pharmacokinet; 2013; 28(5):398-405. PubMed ID: 23438946
[TBL] [Abstract][Full Text] [Related]
15. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.
Kamdem LK; Streit F; Zanger UM; Brockmöller J; Oellerich M; Armstrong VW; Wojnowski L
Clin Chem; 2005 Aug; 51(8):1374-81. PubMed ID: 15951320
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
17. Effect of hepar-protecting Wuzhi capsule on pharmacokinetics and dose-effect character of tacrolimus in healthy volunteers.
Teng F; Wang W; Zhang W; Qu J; Liu B; Chen J; Liu S; Li M; Chen W; Wei H
Biopharm Drug Dispos; 2022 Aug; 43(4):119-129. PubMed ID: 35180322
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human CYP3A4 and CYP3A5 enzymes by gomisin C and gomisin G, two lignan analogs derived from Schisandra chinensis.
Zhao J; Sun T; Wu JJ; Cao YF; Fang ZZ; Sun HZ; Zhu ZT; Yang K; Liu YZ; Gonzalez FJ; Yin J
Fitoterapia; 2017 Jun; 119():26-31. PubMed ID: 28344076
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
20. Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.
Chen X; Wang D; Xu H; Li Z
J Clin Pharm Ther; 2020 Apr; 45(2):309-317. PubMed ID: 31755126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
